期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: Influence of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC 被引量:4
1
作者 Andreas Geier Carsten Gartung +3 位作者 Christoph G.Dietrich Hermann E.Wasmuth patrick reinartz Siegfried Matern 《World Journal of Gastroenterology》 SCIE CAS CSCD 2003年第12期2681-2685,共5页
AIM:To investigate the systemic availability of budesonide in a patient with Child A cirrhosis due to autoimmune hepatitis (AIH) and primary hepatocellular carcinoma,who developed serious side effects. METHODS:Serum l... AIM:To investigate the systemic availability of budesonide in a patient with Child A cirrhosis due to autoimmune hepatitis (AIH) and primary hepatocellular carcinoma,who developed serious side effects. METHODS:Serum levels of budesonide,6β-OH-budesonide and 16α-OH-prednisolon were measured by HPLC/MS/MS; portosystemic shunt-index (SI) was determined by 99mTc nuclear imaging.All values were compared with a matched control patient without side effects. RESULTS:Serum levels of budesonide were 13-fold increased in the index patient.The ratio between serum levels of the metabolites 6β-OH-budesonide and 16α-OH- prednisolone,respectively,and serum levels of budesonide was diminished (1.0 vs.4.0 for 6β-OH-budesonide,4.2 vs. 10.7 for 16α-OH-prednisolone).Both patients had portosystemic SI (5.7 % and 3.1%) within the range of healthy subjects.CONCLUSION:Serum levels of budesonide Vary uP to 13-fold in AIH Patients with Child A eirrhosis in the absenee ofrelevant Portosystemic shunting.Redueed hePatiemetabolism,as indicated by redueed metabolite-to-drugratio,rather than Portosystemie shunting may explainsystemic side effects of this drug in cirrhosis 展开更多
关键词 Portasystemic Shunt Surgical Aged Anti-Inflammatory Agents BUDESONIDE Carcinoma Hepatocellular Female Hepatitis Autoimmune Humans Liver Liver Neoplasms Research Support Non-U.S. Gov't
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部